Lead Product(s): Adalimumab
Therapeutic Area: Immunology
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: DKSH Switzerland
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 24, 2020
Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will oversee its registration and commercialization.